All In Biotech

NDA 021395 · Boehringer Ingelheim

Spiriva

Tiotropium Bromide · Inhalation

Novel

Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jan 30, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

347

124 Phase 3, 2 recruiting

FAERS reports

136,778

68,481 serious, 9,823 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2025.

SPIRIVA HANDIHALER (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HANDIHALER is indicated to reduce exacerbations in COPD patients. SPIRIVA HANDIHALER is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1 )

Mechanism: Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SPIRIVA · TIOTROPIUM BROMIDE EQ 0.018MG BASE/INH · POWDER, INHALATION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tiotropium" as an intervention, any sponsor and status, largest first.

All 347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • incorrect route of drug administration23,320
  • dyspnoea22,675
  • asthma11,105
  • drug ineffective9,516
  • cough8,787
  • pneumonia8,561
  • wheezing6,931
  • chronic obstructive pulmonary disease6,316
  • product quality issue5,982
  • fatigue5,465
  • off label use4,786
  • malaise4,629

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,291
20052,059
20061,844
20072,925
20085,102
20095,565
20106,479
20116,242
20127,661
20139,766
201410,467
201512,811
201612,445
20178,460
20187,430
20197,135
20206,729
20216,632
20224,487
20233,547
20243,258
20252,707
20261,736

Recalls

5 FDA enforcement reports for this application.

  • Jan 26, 2022 · Class II · Terminated

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Dec 14, 2017 · Class II · Terminated

    Failed Stability Specifications

  • Mar 27, 2014 · Class III · Terminated

    Defective Delivery System: Potential for dose delivery out of specification due to interation of the drug product powder with the lubricant on the interior of the capsule shell.

  • Aug 30, 2013 · Class III · Terminated

    Presence of Foreign Substance: This recall is being conducted due to the potential for extrinsic foreign particles in the API used to manufacture SPIRIVA Handihaler

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 590 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.